BeOne Medicines AG research snapshot
ONC AI stock analysis as of the August 2, 2026 data cutoff reads BeOne Medicines AG as a profitable global oncology company whose commercial engine is led by BRUKINSA while its solid tumor pipeline creates both optionality and event risk. The stock closed at $316.01 on July 31, 2026, down 1.88% on the day, and implied a market capitalization near $35.13 billion, re-verified during this full refresh as $316.01 times 111.17 million shares with a 0.00% deviation. The latest reported quarter is Q1 2026, with revenue of $1.513 billion up 35.46% year over year and GAAP net income of $227.36 million, while trailing twelve month revenue reached about $5.67 billion and TTM net income about $513 million. BeOne holds a net cash position near $2.74 billion at March 31, 2026, and 28 analysts rate the stock a Strong Buy with an average target of $415.64, about 31.5% above the current price. Recent catalysts include positive Phase 3 MANGROVE results for BRUKINSA in frontline mantle cell lymphoma, an FDA orphan designation for the PRMT5 inhibitor in pancreatic cancer, and a more than $1 billion total U.S. manufacturing investment. Q2 2026 results are scheduled for August 5, 2026. The page presents a scenario framework, not a certain price prediction, and is for information only.
Current price
$316.01
Market cap
$35.13 billion
AI score
73 / 100
Rating
Profitable oncology growth with strong analyst support and a premium valuation
Trend status
Uptrend holding above key moving averages with neutral momentum into the August 5 earnings date
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BeOne commercializes oncology medicines globally, led by BRUKINSA, with TEVIMBRA, XGEVA, BLINCYTO, KYPROLIS, and POBEVCY contributing, and funds a broad hematology and solid tumor pipeline. | High |
| Moat | The moat rests on clinical evidence, regulatory approvals, BRUKINSA leadership in BTK inhibition, manufacturing scale with over $1 billion U.S. investment, commercial reach, and accumulated development capability rather than a permanent monopoly. | Medium-high |
| Management | Founder-led management has scaled global commercialization and delivered profitable quarters, but must preserve capital discipline while the pipeline expands and share count rises 8.16% year over year. | Medium |
| Financial trend | Q1 2026 revenue rose 35.46% year over year to $1.513 billion with GAAP net income of $227.36 million and EPS of $1.95, while TTM revenue reached about $5.67 billion with TTM net income near $513 million and positive free cash flow. | High |
| Valuation | At about 71.75x trailing PE, 45.42x forward PE, and 38.75x EV/EBITDA, the market already prices in continued execution and pipeline progress, leaving a narrow margin for error. | Medium-low |
| Technical trend | ONC closed at $316.01 on July 31, 2026, just above the 20-day and 200-day moving averages near $314.83 and $314.02, with the 50-day near $294.51 and 100-day near $297.20, and a neutral 14-day RSI near 55.56. | Medium |
| Risk level | Clinical, regulatory, pricing, competition, China exposure, share dilution, pipeline spending, and valuation compression are material risks, with Q2 2026 earnings on August 5, 2026 an immediate event. | High |
| AI confidence | High for reported financial data and business mapping that cross-checked across StockAnalysis.com, Macrotrends, and Barchart, but lower for drug approvals, trial readouts, and future market returns. | High data confidence |
| Investment certainty | Medium certainty because a strong reported quarter and a net cash balance sheet do not remove the binary risks embedded in oncology development and an elevated valuation. | Medium |
ONC AI stock forecast
The ONC AI stock forecast uses ranges around the $316.01 July 31, 2026 closing price rather than a point target, and it explicitly flags the August 5, 2026 Q2 earnings report as an immediate event. The reported Q1 result, BRUKINSA growth, pipeline execution, regulatory events, competition, and the valuation multiple can all move the outcome.
$410 to $470
More likely if BRUKINSA keeps growing, the solid tumor pipeline reads positively, the PRMT5 program advances, margins hold, dilution slows, and investors keep assigning a premium multiple to the oncology platform, moving toward targets such as RBC at $451 and the consensus high of $501.30.
$345 to $410
More likely if commercial execution remains solid, Q2 2026 results meet the strong consensus, R&D spending and competition keep valuation expectations balanced, and the stock trades near the consensus average target of $415.64.
$255 to $320
More likely if product growth slows, a trial or regulatory event disappoints, a competitor such as Summit Therapeutics gains share, pricing pressure rises, dilution continues, or the market compresses the multiple toward the 52-week low of $253.95 and below the analyst low target of $340.
ONC AI technical analysis
ONC AI technical analysis starts from the $316.01 July 31, 2026 closing price, which sat just above the 20-day moving average near $314.83 and the 200-day moving average near $314.02, with the 50-day near $294.51 and the 100-day near $297.20 forming a support cluster below. The 14-day RSI near 55.56 was neutral and 14-day ADX near 28.96 showed a moderate trend. The 52-week range is $253.95 to $385.22.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $316.01 | StockAnalysis.com and Macrotrends both confirmed the $316.01 close at the July 31, 2026 market close. |
| Near support | $294 to $298 | The 50-day moving average near $294.51 and the 100-day near $297.20 form a support cluster. It is not a guaranteed floor. |
| Near resistance | $322 to $330 | The prior close of $322.08 and the July 31 day high of $320.86 mark the nearest overhead zone before the 52-week high area. |
| Major resistance | $385.22 | The 52-week high is the main overhead level, about 21.9% above the current price per Macrotrends. |
| 20-day moving average | $314.83 | Barchart reported the 20-day moving average near $314.83, roughly at the current price. |
| 50-day moving average | $294.51 | StockAnalysis.com and Barchart both placed the 50-day moving average near $294.51, below price and confirming the medium-term uptrend. |
| 100-day moving average | $297.20 | Barchart reported the 100-day moving average near $297.20, part of the support cluster. |
| 200-day moving average | $314.02 | StockAnalysis.com and Barchart both reported the 200-day trend line near $314.02, just below the current price. |
| Momentum | RSI near 56, ADX near 29 | 14-day RSI near 55.56 was neutral, and 14-day ADX near 28.96 showed a moderate trend on Barchart as of July 31, 2026. |
| Volume | About 375,000 average shares | Barchart listed 20-day average volume near 374,895 shares and StockAnalysis.com near 374,937, useful for checking breakout quality. |
| Volatility | Moderate, elevated near events | Barchart reported 14-day historic volatility near 22.91% and a 14-day ATR near $9.06, with drug and earnings news able to cause gaps. |
| Invalidation | Sustained close below $294 | A confirmed break below the $294 to $298 support cluster would weaken the short-term uptrend; a break below the 52-week low of $253.95 would turn it bearish. |
ONC AI trading strategy
The ONC AI trading strategy is a rules-based research framework, not personalized advice. Pair any setup with position sizing, event-risk awareness, and current filing and chart checks, especially around the August 5, 2026 Q2 earnings report.
Wait for ONC to hold above the $294 to $298 support cluster and to clear the $322 to $330 zone on rising volume, with the 50-day and 200-day moving averages rising to confirm improving momentum.
A failed breakout or a sustained close below the defined support zone invalidates the setup.
If ONC approaches the $294 to $298 support cluster without a business or clinical thesis break, compare the move with the latest BRUKINSA sales, cash position, guidance, and the upcoming trial and earnings calendar before acting.
Do not average down through a negative regulatory, safety, or trial-data change without reassessing the thesis.
Track quarterly product revenue, gross margin, R&D, the August 5, 2026 Q2 report, regulatory decisions, trial data such as MANGROVE and the PRMT5 program, competitor readouts, and dilution pace.
Reduce exposure assumptions before binary events when a gap through a stop would exceed the planned loss.
Investment research summary
BeOne sells oncology medicines worldwide, led by BRUKINSA, and reinvests commercial cash generation into hematology and solid tumor development including a PRMT5 program granted FDA orphan designation.
Clinical data, approved medicines, regulatory infrastructure, manufacturing with over $1 billion U.S. investment, and a global commercial organization make replication difficult, but patent and clinical advantages can erode.
The thesis can fail through weaker BRUKINSA growth, clinical setbacks, approval delays, safety signals, payer pressure, competitor launches such as Summit ivonescimab, continued dilution, or escalating development costs.
John V. Oyler co-founded and leads BeOne. The key test is whether the company converts a large pipeline into durable returns without losing cost discipline as share count rises 8.16% year over year.
Oncology demand and targeted therapy innovation support long-run opportunity, while payer scrutiny, trial complexity, and fast-moving standards of care constrain predictability.
At $316.01, the market capitalization was verified at about $35.13 billion. At about 71.75x trailing PE and 45.42x forward PE, the valuation depends on continued product growth and pipeline value, leaving a limited margin for execution errors.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ONC closing price | $316.01 at the July 31, 2026 close | StockAnalysis.com real-time quote, cross-checked with Macrotrends | August 2, 2026 |
| Market capitalization | $35.13 billion, computed as $316.01 x 111.17 million shares with 0.00% deviation | StockAnalysis.com share statistics and financial_rigor.py | August 2, 2026 |
| Q1 2026 revenue | $1.513 billion, up 35.46% year over year from $1.117 billion in Q1 2025 | StockAnalysis.com quarterly financials | August 2, 2026 |
| Q1 2026 GAAP net income | $227.36 million, with EPS of $1.95 | StockAnalysis.com quarterly financials | August 2, 2026 |
| Q1 2026 BRUKINSA revenue | $1.095 billion of total Q1 2026 product revenue | StockAnalysis.com quarterly financials by segment | August 2, 2026 |
| TTM revenue | $5.67 billion, up 36.75% | StockAnalysis.com financials overview | August 2, 2026 |
| TTM net income | $513.02 million, with TTM EPS of $4.40 | StockAnalysis.com statistics | August 2, 2026 |
| FY2025 revenue | $5.343 billion, up 40.23% from $3.810 billion in FY2024 | StockAnalysis.com financials and Macrotrends | August 2, 2026 |
| FY2025 net income | $286.93 million, versus a -$644.79 million loss in FY2024 | StockAnalysis.com financials | August 2, 2026 |
| Cash and investments | $4.792 billion at March 31, 2026 | StockAnalysis.com balance sheet | August 2, 2026 |
| Total debt | $2.053 billion at March 31, 2026 | StockAnalysis.com balance sheet | August 2, 2026 |
| Net cash | $2.738 billion at March 31, 2026, about $24.63 per share, computed as cash and investments of $4.792 billion minus total debt of $2.053 billion | StockAnalysis.com statistics and balance sheet | August 2, 2026 |
| TTM operating cash flow and free cash flow | Operating cash flow of $1.285 billion, capital expenditures of $170.22 million, free cash flow of $1.111 billion | StockAnalysis.com cash flow statement | August 2, 2026 |
| Valuation check | 71.75x trailing PE, 45.42x forward PE, 6.12x sales, 7.38x book value, 31.52x free cash flow, 38.75x EV/EBITDA, no dividend | StockAnalysis.com statistics | August 2, 2026 |
| Profitability and returns | TTM gross margin 88.31%, operating margin 11.95%, profit margin 8.94%, ROE 12.42%, ROIC 28.01% | StockAnalysis.com statistics | August 2, 2026 |
| Analyst consensus | Strong Buy with an average target of $415.64 across 28 analysts, low $340 and high $501.30, median $414.46 | StockAnalysis.com forecast | August 2, 2026 |
| Analyst rating mix, July 2026 | 20 Strong Buy and 8 Buy out of 28 analysts, 0 Hold, 0 Sell | StockAnalysis.com forecast recommendation trends | August 2, 2026 |
| Recent analyst target updates | J.P. Morgan $415 to $425 on July 23, 2026, Morgan Stanley $395, RBC Capital $436 to $451, Truist $413 to $416, Jefferies upgraded to Buy at $380, Barclays $409 to $403 | StockAnalysis.com forecast | August 2, 2026 |
| FY2026 and FY2027 consensus estimates | FY2026 revenue estimate $6.51 billion with adjusted EPS $0.50, FY2027 revenue $7.45 billion with adjusted EPS $0.76 | StockAnalysis.com forecast | August 2, 2026 |
| Short interest | 926,986 shares short, 1.31% of shares outstanding, 2.80 days to cover | StockAnalysis.com statistics short selling | August 2, 2026 |
| Share count and dilution | 111.17 million shares outstanding, up 8.16% year over year and 0.34% quarter over quarter | StockAnalysis.com statistics | August 2, 2026 |
| 52-week range | $253.95 to $385.22, with an average 52-week price of about $315.78 | StockAnalysis.com and Macrotrends price history | August 2, 2026 |
| Technical snapshot | 20-day SMA near $314.83, 50-day SMA near $294.51, 100-day SMA near $297.20, 200-day SMA near $314.02, 14-day RSI near 55.56, 14-day ADX near 28.96, 14-day historic volatility near 22.91% | Barchart and StockAnalysis.com technical snapshots | August 2, 2026 |
| Next earnings date | Q2 2026 results scheduled for August 5, 2026, before market open | StockAnalysis.com overview | August 2, 2026 |
This ONC AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 2, 2026, may be incomplete, and can be wrong if clinical results, filings, market prices, company events, or macro conditions change. The Q2 2026 earnings report due August 5, 2026 was not yet released at the cutoff.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
